UNSPSC 51292913: Opipramol

This classification denotes an anxiolytic and antidepressant agent with the molecular formula C23H29N3O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier D23ZXO613C, chemically known as 2-naphthaleneacetic acid, 6-methoxy-.alpha.-methyl-, (s)- but generally known as opipramol, which bears US NIH Compound Identifier 1302. European Medicines Agency schedules Opipramol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09450MIG. The term OPIPRAMOL is an International Non-Proprietary Name.

UNSPSC 51292913 Opipramol is a Commodity code that in recent state and local procurement activity covers the supply of pharmaceutical products including naloxone, generic multi-source pharmaceuticals, and over-the-counter drugs to public health agencies and state benefit programs. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances representing multiple jurisdictions. Work solicited under this code ranges from direct procurement of specific drug units for community health initiatives to manufacturer-level contracting for generic pharmaceutical distribution through authorized wholesalers serving state and local facilities. Vendors must typically comply with FDA requirements, current Good Manufacturing Practices, the Drug Supply Chain Security Act, E-Verify employment verification, drug-free workplace certification, and federal compliance mandates when procurement is federally funded.

Recent activity spans Florida, Texas, and Minnesota-led multistate cooperative purchasing. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a response deadline of July 26, 2023—a bid with a two-year initial term and optional one-year renewal. The Texas Health and Human Services Commission issued RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, marking an exploratory phase before formal RFP issuance. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) released RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026, to establish multiple contracts for generic pharmaceuticals and OTC products across participating state and local government facilities, including Oregon, with awarded vendors taking effect July 1, 2026. MMCAP contracts carry a two-year initial term for new responders and impose a 3 percent administrative fee on all purchases.